ISSN:
1442-2042
Quelle:
Blackwell Publishing Journal Backfiles 1879-2005
Thema:
Medizin
Notizen:
The present study was designed to ascertain retrospectively the validity of ursodeoxycholic acid (UDCA) in the treatment of prostate cancer in terms of prophylactic effects on the occurrence of flutamide-induced hepatopathy in a large number of patients surveyed in a multi-center cooperative study.〈section xml:id="abs1-3"〉〈title type="main"〉Methods:One hundred and eighty-one patients (74.1 ± 4.9 years) with prostate cancer treated with flutamide with (n = 70) or without (n = 111) UDCA were retrospectively evaluated and the occurrence of hepatopathy was compared between these two patient groups.〈section xml:id="abs1-4"〉〈title type="main"〉Results:Between patients treated with UDCA and those without it, no significant differences were noted in age, clinical stage, grade, duration of flutamide administration and serum prostate-specific antigen (PSA) levels before treatment. However, there were significant differences in the presence or absence of previous treatments and treatments used together with flutamide. The incidence of hepatopathy was 11.4% (8/70) in patients with UDCA and 32.4% (36/111) in those without it, showing a statistically significant difference (P 〈 0.05). The hepatopathy-free rate obtained by the Kaplan–Meier method was also significantly higher in patients with UDCA (88.4% 1 year following flutamide administration) than that in those without it (59.6%) (P 〈 0.005).〈section xml:id="abs1-5"〉〈title type="main"〉Conclusion:These results suggest that UDCA has a prophylactic effect against flutamide-induced hepatopathy in patients with prostate cancer.
Materialart:
Digitale Medien
URL:
http://dx.doi.org/10.1046/j.1442-2042.2002.00412.x
